Drugs / MTX-474
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06535841 | Jul 2024 → Apr 2025 | — | Mediar Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07287670 | Apr 2026 → Dec 2028 expected | diffuse cutaneous systemic sclerosis | Mediar Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX-474 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07287670 ↗ |
| Action | Inhibit | “has demonstrated ability to block phosphorylation” NCT06535841 ↗ |
| Modality | Monoclonal antibody | “immunoglobin G1 (IgG1) monoclonal antibody” NCT06535841 ↗ |
| Route | Intravenous | “receive MTX-474 or a matching placebo by intravenous (IV) infusion” NCT07287670 ↗ |